Search research articles
Contact Us
Filters
Showing results (41-50 of 97) with videos related to
Page
of 10
Sort By:
Journal of the American College of Cardiology
|
April 3, 2014
Anti-PCSK9 monotherapy for hypercholesterolemia: the MENDEL-2 randomized, controlled phase III clinical trial of evolocumab
Michael J Koren, Pernille Lundqvist, Michael Bolognese, et al.
American Heart Journal
|
February 28, 2016
Rationale and design of the Further cardiovascular OUtcomes Research with PCSK9 Inhibition in subjects with Elevated Risk trial
Marc S Sabatine, Robert P Giugliano, Anthony Keech, et al.
European Heart Journal
|
December 19, 2018
Persistent arterial wall inflammation in patients with elevated lipoprotein(a) despite strong low-density lipoprotein cholesterol reduction by proprotein convertase subtilisin/kexin type 9 antibody treatment
Lotte C A Stiekema, Erik S G Stroes, Simone L Verweij, et al.
Journal of Clinical Pharmacology
|
September 27, 2016
Evaluation of Evolocumab (AMG 145), a Fully Human Anti-PCSK9 IgG2 Monoclonal Antibody, in Subjects With Hepatic Impairment
John P Gibbs, J Greg Slatter, Ogo Egbuna, et al.
The Journal of Biological Chemistry
|
September 25, 2002
Identification of a novel family of cell-surface proteins expressed in human vascular endothelium
Ruey-Bing Yang, Chi Kin Domingos Ng, Scott M Wasserman, et al.
Circulation
|
March 3, 2017
Pooled Safety Analysis of Evolocumab in Over 6000 Patients From Double-Blind and Open-Label Extension Studies
Peter P Toth, Olivier Descamps, Jacques Genest, et al.
JACC. Cardiovascular Imaging
|
December 19, 2021
Determinants of Plaque Progression Despite Very Low Low-Density Lipoprotein-Cholesterol Levels With the PCSK9 Inhibitor, Evolocumab
Satoshi Honda, Rishi Puri, Todd Anderson, et al.
European Heart Journal
|
August 8, 2007
Randomized, double-blind, placebo-controlled study to evaluate the effect of two dosing regimens of darbepoetin alfa in patients with heart failure and anaemia
Dirk J van Veldhuisen, Kenneth Dickstein, Alain Cohen-Solal, et al.
Journal of Cell Science
|
January 28, 2014
The role of Hath6, a newly identified shear-stress-responsive transcription factor, in endothelial cell differentiation and function
Fang Fang, Scott M Wasserman, Jesus Torres-Vazquez, et al.
Journal of Cardiovascular Pharmacology and Therapeutics
|
May 18, 2018
Comparison of LDL-C Reduction Using Different Evolocumab Doses and Intervals: Biological Insights and Treatment Implications
Scott M Wasserman, Marc S Sabatine, Michael J Koren, et al.
Page
of 10
Search research articles
Search
Showing results (41-50 of 97) with videos related to
Sort By:
Page
of 10
Journal of the American College of Cardiology
|
April 3, 2014
Anti-PCSK9 monotherapy for hypercholesterolemia: the MENDEL-2 randomized, controlled phase III clinical trial of evolocumab
Michael J Koren, Pernille Lundqvist, Michael Bolognese, et al.
American Heart Journal
|
February 28, 2016
Rationale and design of the Further cardiovascular OUtcomes Research with PCSK9 Inhibition in subjects with Elevated Risk trial
Marc S Sabatine, Robert P Giugliano, Anthony Keech, et al.
European Heart Journal
|
December 19, 2018
Persistent arterial wall inflammation in patients with elevated lipoprotein(a) despite strong low-density lipoprotein cholesterol reduction by proprotein convertase subtilisin/kexin type 9 antibody treatment
Lotte C A Stiekema, Erik S G Stroes, Simone L Verweij, et al.
Journal of Clinical Pharmacology
|
September 27, 2016
Evaluation of Evolocumab (AMG 145), a Fully Human Anti-PCSK9 IgG2 Monoclonal Antibody, in Subjects With Hepatic Impairment
John P Gibbs, J Greg Slatter, Ogo Egbuna, et al.
The Journal of Biological Chemistry
|
September 25, 2002
Identification of a novel family of cell-surface proteins expressed in human vascular endothelium
Ruey-Bing Yang, Chi Kin Domingos Ng, Scott M Wasserman, et al.
Circulation
|
March 3, 2017
Pooled Safety Analysis of Evolocumab in Over 6000 Patients From Double-Blind and Open-Label Extension Studies
Peter P Toth, Olivier Descamps, Jacques Genest, et al.
JACC. Cardiovascular Imaging
|
December 19, 2021
Determinants of Plaque Progression Despite Very Low Low-Density Lipoprotein-Cholesterol Levels With the PCSK9 Inhibitor, Evolocumab
Satoshi Honda, Rishi Puri, Todd Anderson, et al.
European Heart Journal
|
August 8, 2007
Randomized, double-blind, placebo-controlled study to evaluate the effect of two dosing regimens of darbepoetin alfa in patients with heart failure and anaemia
Dirk J van Veldhuisen, Kenneth Dickstein, Alain Cohen-Solal, et al.
Journal of Cell Science
|
January 28, 2014
The role of Hath6, a newly identified shear-stress-responsive transcription factor, in endothelial cell differentiation and function
Fang Fang, Scott M Wasserman, Jesus Torres-Vazquez, et al.
Journal of Cardiovascular Pharmacology and Therapeutics
|
May 18, 2018
Comparison of LDL-C Reduction Using Different Evolocumab Doses and Intervals: Biological Insights and Treatment Implications
Scott M Wasserman, Marc S Sabatine, Michael J Koren, et al.
Page
of 10